Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

10 Apr 2026, 11:38 by Teresa Graham · The Cerbat Gem

Organon & Co. (NYSE:OGN – Get Free Report) was the target of some unusual options trading activity on Friday. Investors bought 20,849 call options on the company. This represents an increase of approximately 537% compared to the typical volume of 3,274 call options.

Organon & Co. Stock Up 25.5%

Shares of NYSE OGN traded up $1.76 during trading on Friday, hitting $8.67. The stock had a trading volume of 22,361,115 shares, compared to its average volume of 5,185,998. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.24. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. The company has a market capitalization of $2.26 billion, a PE ratio of 12.22, a PEG ratio of 0.54 and a beta of 0.67. The firm has a fifty day moving average of $6.93 and a two-hundred day moving average of $7.78.

Organon & Co. (NYSE:OGN – Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the previous year, the company earned $0.90 EPS. The business’s revenue was down 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were paid a $0.02 dividend. The ex-dividend date was Monday, February 23rd. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. Organon & Co.’s dividend payout ratio is presently 11.27%.

Institutional Trading of Organon & Co.

Institutional investors have recently made changes to their positions in the company. Sector Gamma AS bought a new stake in shares of Organon & Co. in the 3rd quarter worth $5,807,000. Gotham Asset Management LLC boosted its holdings in shares of Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after buying an additional 1,007,691 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after buying an additional 3,650,860 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Organon & Co. in the 3rd quarter worth about $2,000,000. Finally, Douglas Lane & Associates LLC boosted its holdings in shares of Organon & Co. by 40.5% in the 3rd quarter. Douglas Lane & Associates LLC now owns 443,876 shares of the company’s stock worth $4,741,000 after buying an additional 127,924 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on OGN. Barclays boosted their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $8.50.

Read Our Latest Stock Report on OGN

Organon & Co. Company Profile

(Get Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.